Arcturus Therapeutics has signed an agreement to supply the its COVID-19 vaccine candidate, LUNAR-COV1D, to the Israeli Ministry of Health.
Delivery of the vaccine candidate is contingent upon achievement of near term clinical and regulatory milestones and other conditions to be set forth in the definitive supply agreement.
The government of Israel is responsible for distributing the vaccine to its citizens subject to approval by their Ministry of Health.
The Israeli Ministry of Health is the second government authority to reserve doses of LUNAR-COV19.
The parties intend to finalise a comprehensive supply agreement within 30 days.
Arcturus previously announced its partnership with Duke-NUS in Singapore, in which the Company recently received Clinical Trial Application (CTA) approval to proceed with a Phase 1/2 trial.
